抗体药物偶联物在卵巢癌治疗中的应用与挑战

Application and challenges of antibody-drug conjugate in the treatment of ovarian cancer

摘要

近年来，抗体药物偶联物（ADC）凭借其靶向递送与免疫调节的双重优势，成为卵巢癌治疗的研究热点。本综述系统阐述ADC 的作用机制，即通过抗体与抗原特异性结合实现细胞毒性载荷的精准递送，重点探讨其激活抗肿瘤免疫应答、克服免疫治疗耐药性的潜力，并讨论ADC 与免疫检查点抑制剂等免疫治疗手段的协同应用策略，梳理针对卵巢癌特定靶点的ADC药物最新临床试验进展，同时展望未来研究方向，提出应致力于优化ADC分子设计、提升疗效与安全性，以及深入探索其与其他治疗手段联合应用的可行性。

Abstract

In recent years, antibody-drug conjugate (ADC) have emerged as a focus of research in ovarian cancer therapeutics, leveraging their dual capabilities in targeted payload delivery and immunomodulation. This review systematically elucidated the mechanistic basis of ADC, wherein cytotoxic payloads are precisely delivered through antibody-mediated antigen recognition. We further examined the immunostimulatory potential of ADC in eliciting anti-tumor immune responses and circumventing resistance mechanisms associated with conventional immunotherapy. Additionally, synergistic strategies integrating ADC with immune checkpoint inhibitors and other immunotherapeutic agents are discussed, alongside a comprehensive overview of recent clinical trial developments targeting ovarian cancer-specific antigens. Finally, we proposed future directions centered on rational optimization of ADC architectures, improvement of therapeutic indices, and rigorous evaluation of combination therapeutic modalities.

关键词

抗体药物偶联物 / 卵巢癌 / 免疫激活 / 靶向治疗 / 联合策略

Key words

antibody-drug conjugate / ovarian cancer / immune activation / targeted therapy / combined strategy

参考文献

[1] MARCHETTI C， MUZII L， ROMITO A， et al. First—line treatment of women with advanced ovarian cancer：focus on bevacizumab[J]. OncoTargets and therapy， 2019， 12：1095-1103.

[2] LE SAUX O， RAY—COQUARD I， LABIDI—GALY S I. Challenges for immunotherapy for the treatment of platinum resistant ovarian cancer[J]. Seminars in cancer biology， 2021， 77：127-143.

[3] TARANTINO P， CARMAGNANI PESTANA R， CORTI C， et al. Antibody—drug conjugates：smart chemotherapy delivery across tumor histologies[J]. Ca：a cancer journal for clinicians， 2022， 72（2）：165-182.

[4] HEO Y A. Mirvetuximab soravtansine：first approval[J]. Drugs， 2023， 83（3）：265-273.

[5] DRAGO J Z， MODI S N， CHANDARLAPATY S. Unlocking the potential of antibody—drug conjugates for cancer therapy[J]. Nature reviews clinical oncology， 2021， 18（6）：327-344.

[6] FU Z W， LI S J， HAN S F， et al. Antibody drug conjugate：the “biological missile” for targeted cancer therapy[J]. Signal transduction and targeted therapy， 2022， 7（1）：93.

[7] ABELMAN R O， WU B G， SPRING L M， et al. Mechanisms of resistance to antibody—drug conjugates[J]. Cancers， 2023， 15（4）：1278.

[8] TSUCHIKAMA K， ANAMI Y， HA S Y Y， et al. Exploring the next generation of antibody—drug conjugates[J]. Nature reviews clinical oncology， 2024， 21（3）：203-223.

[9] CONILH L， SADILKOVA L， VIRICEL W， et al. Payload diversification：a key step in the development of antibody—drug conjugates[J]. Journal of hematology & oncology， 2023， 16（1）：3.

[10] EL BAIRI K， AL JARROUDI O， AFQIR S. Revisiting antibody—drug conjugates and their predictive biomarkers in platinum—resistant ovarian cancer[J]. Seminars in cancer biology， 2021， 77：42-55.

[11] LIU X L， MA L N， LI J， et al. Trop2—targeted therapies in solid tumors：advances and future directions[J]. Theranostics， 2024， 14（9）：3674-3692.

[12] BARDIA A， HURVITZ S A， TOLANEY S M， et al. Sacituzumab govitecan in metastatic triple—negative breast cancer[J]. New England journal of medicine， 2021， 384（16）：1529-1541.

[13] WU Y， ZHU M， SUN B H， et al. A humanized trivalent nectin—4—targeting nanobody drug conjugate displays potent antitumor activity in gastric cancer[J]. Journal of nanobiotechnology， 2024， 22（1）：256.

[14] QIAN J， LESAVAGE B L， HUBKA K M， et al. Cancer—associated mesothelial cells promote ovarian cancer chemoresistance through paracrine osteopontin signaling[J]. Journal of clinical investigation， 2021， 131（16）：e146186.

[15] HASSAN R， BLUMENSCHEIN G R Jr， MOORE K N， et al. First—in—human，multicenter，phase Ⅰ dose—escalation and expansion study of anti—mesothelin antibody—drug conjugate anetumab ravtansine in advanced or metastatic solid tumors[J]. Journal of clinical oncology， 2020， 38（16）：1824-1835.

[16] ALQAISI H A， COHN D E， CHERN J Y， et al. Randomized phase Ⅱstudy of bevacizumab with weekly anetumab ravtansine or weekly paclitaxel in platinum—resistant/refractory high—grade ovarian cancer （NCI trial）[J]. Clinical cancer research， 2025， 31（6）：993-1001.

[17] MAI Y S， SU J Y， YANG C， et al. The strategies to cure cancer patients by eradicating cancer stem—like cells[J]. Molecular cancer， 2023， 22（1）：171.

[18] ALIZADEH H， AKBARABADI P， DADFAR A， et al. A comprehensive overview of ovarian cancer stem cells：correlation with high recurrence rate，underlying mechanisms，and therapeutic opportunities[J]. Molecular cancer， 2025， 24（1）：135.

[19] PAZ—ARES L， CHAMPIAT S， LAI W V， et al. Tarlatamab，a first—in—class dll3—targeted bispecific t—cell engager，in recurrent small—cell lung cancer：an open—label，phase i study[J]. Journal of clinical oncology， 2023， 41（16）：2893-2903.

[20] HARRINGTON B S， HE Y W， KHAN T， et al. Anti—CDCP1 immuno—conjugates for detection and inhibition of ovarian cancer[J]. Theranostics， 2020， 10（5）：2095-2114.

[21] LEE J Y， JONUS H C， SADANAND A， et al. Identification and targeting of protein tyrosine kinase 7 （PTK7） as an immunotherapy candidate for neuroblastoma[J]. Cell reports medicine， 2023， 4（6）：101091.

[22] LACEY K， GREENER M R， MARAK T R， et al. Protein tyrosine kinase 7 （PTK7） in breast cancer：a retrospective analysis of tumour expression and association with clinical outcome[J]. Cancers 2024， 16（18）：3206.

[23] JI J， QIAN Q L， CHENG W H， et al. FOXP4—mediated induction of PTK7 activates the Wnt/β—catenin pathway and promotes ovarian cancer development[J]. Cell death & disease， 2024， 15（5）：332.

[24] MAITLAND M L， SACHDEV J C， SHARMA M R， et al. First—in—human study of pf—06647020 （cofetuzumab pelidotin），an antibody—drug conjugate targeting protein tyrosine kinase 7，in advanced solid tumors[J]. Clinical cancer research， 2021， 27（16）：4511-4520.

[25] KONG F E， LI G M， TANG Y Q， et al. Targeting tumor lineage plasticity in hepatocellular carcinoma using an anti—CLDN6 antibody—drug conjugate[J]. Science translational medicine， 2021， 13（579）：eabb6282.

[26] MCDERMOTT M S J， O’BRIEN N A， HOFFSTROM B， et al. Preclinical efficacy of the antibody—drug conjugate CLDN6—23—ADC for the treatment of CLDN6—positive solid tumors[J]. Clinical cancer research， 2023， 29（11）：2131-2143.

[27] RAY U， PATHOULAS C L， THIRUSANGU P， et al. Exploiting LRRC15 as a novel therapeutic target in cancer[J]. Cancer research， 2022， 82（9）：1675-1681.

[28] RAY U， JUNG D—B， JIN L， et al. Targeting LRRC15 inhibits metastatic dissemination of ovarian cancer[J]. Cancer research， 2022， 82（6）：1038-1054.

[29] FABRE M， FERRER C， DOMÍNGUEZ—HORMAETXE S， et al. OMTX705，a novel FAP—targeting ADC demonstrates activity in chemotherapy and pembrolizumab—resistant solid tumor models[J]. Clinical cancer research， 2020， 26（13）：3420-3430.

[30] MORI Y， OKIMOTO Y， SAKAI H， et al. Targeting PDGF signaling of cancer—associated fibroblasts blocks feedback activation of HIF—1 α and tumor progression of clear cell ovarian cancer[J]. Cell reports medicine， 2024， 5（5）：101532.

[31] YU X L， LONG Y R， CHEN B F， et al. PD—L1/TLR7 dual—targeting nanobody—drug conjugate mediates potent tumor regression via elevating tumor immunogenicity in a host—expressed PD—l1 bias—dependent way[J]. Journal for immunotherapy of cancer， 2022， 10（10）：e004590.

[32] MACGREGOR H L， SAYAD A， ELIA A， et al. High expression of B7—H3 on stromal cells defines tumor and stromal compartments in epithelial ovarian cancer and is associated with limited immune activation[J]. Journal for ImmunoTherapy of cancer， 2019， 7（1）：357.

[33] GITTO S B， WHICKER M， DAVIES G， et al. A B7—H4—targeting antibody—drug conjugate shows antitumor activity in PARPi and platinum—resistant cancers with B7—H4 expression[J]. Clinical cancer research， 2024， 30（8）：1567-1581.

[34] KANDALAFT L E， DANGAJ LANITI D， COUKOS G. Immunobiology of high—grade serous ovarian cancer：lessons for clinical translation[J]. Nature reviews cancer， 2022， 22（11）：640-656.

[35] ZHANG J H， HUANG D， SAW P E， et al. Turning cold tumors hot：from molecular mechanisms to clinical applications[J]. Trends in immunology， 2022， 43（7）：523-545.

[36] 王雪娇， 孙程亮， 杨鹏. 促进冷肿瘤向热肿瘤转变的机制及药物研究进展[J]. 兰州大学学报（医学版）， 2025， 51（9）：1-7.

[37] HEISER R A， CAO A T， ZENG W P， et al. Brentuximab vedotin—driven microtubule disruption results in endoplasmic reticulum stress leading to immunogenic cell death and antitumor immunity[J]. Molecular cancer therapeutics， 2024， 23（1）：68-83.

[38] WITTWER N L， STAUDACHER A H， LIAPIS V， et al. An anti—mesothelin targeting antibody drug conjugate induces pyroptosis and ignites antitumor immunity in mouse models of cancer[J]. Journal for ImmunoTherapy of cancer， 2023， 11（3）：e006274.

[39] MÜLLER P， MARTIN K， THEURICH S， et al. Microtubule—depolymerizing agents used in antibody—drug conjugates induce antitumor immunity by stimulation of dendritic cells[J]. Cancer immunology research， 2014， 2（8）：741-755.

[40] LEE J M， SHIN K S， KOH C H， et al. Inhibition of topoisomerase I shapes antitumor immunity through the induction of monocyte—derived dendritic cells[J]. Cancer letters， 2021， 520：38-47.

[41] AHMED A， TAIT S W G. Targeting immunogenic cell death in cancer[J]. Molecular oncology， 2020， 14（12）：2994-3006.

[42] MUSOLINO A， GRADISHAR W J， RUGO H S， et al. Role of Fcγ receptors in HER2—targeted breast cancer therapy[J]. Journal for ImmunoTherapy of cancer， 2022， 10（1）：e003171.

[43] CHEN W Z， YUAN Y， JIANG X Q. Antibody and antibody fragments for cancer immunotherapy[J]. Journal of controlled release， 2020， 328：395-406.

[44] ANDERSON S， HANSEN N N， LAWRENCE R， et al. Abstract 1766：SGN—ALPV a novel，investigational vedotin adc demonstrates highly effective targeting of oncofetal phos—phatases ALPP and ALPPL2 in preclinical models[J]. Cancer research， 2022， 82（12_Supplement）：1766—1766.

[45] BUKHALID R A， DUVALL J R， LANCASTER K， et al. XMT—2056，a HER2—directed agonist antibody—drug conjugate，induces innate antitumor immune responses by acting on cancer cells and tumor—resident immune cells[J]. Clinical cancer research， 2025， 31（9）：1766-1782.

[46] MATULONIS U A， MOORE K N， MARTIN L P， et al. Mirvetuximab soravtansine，a folate receptor alpha （FRα）—targeting antibody—drug conjugate （ADC），with pembrolizumab in platinum—resistant ovarian cancer （PROC）：initial results of an expansion cohort from FORWARD Ⅱ，a phase Ib study[J]. Annals of oncology， 2018， 29：339-340.

[47] FUENTES—ANTRÀS J， GENTA S， VIJENTHIRA A， et al. Antibody—drug conjugates：in search of partners of choice[J]. Trends in cancer， 2023， 9（4）：339-354.

[48] 褚婷婷， 黄楚君. cGAS—STING 信号通路的调控机制及其在肿瘤发生发展中的作用[J]. 兰州大学学报（医学版）， 2023， 49（1）：1-5.

[49] LI A P， YI M， QIN S， et al. Activating cGAS—STING pathway for the optimal effect of cancer immunotherapy[J]. Journal of hematology & oncology， 2019， 12（1）：35.

[50] MALLI CETINBAS N， MONNELL T， SOOMER—JAMES J， et al. Tumor cell—directed STING agonist antibody—drug conjugates induce typeⅢinterferons and anti—tumor innate immune responses[J]. Nature communications， 2024， 15（1）：5842.

[51] JANKU F， HAN S—W， DOI T， et al. Preclinical characterization and phase Ⅰ study of an anti—HER2—TLR7 immune—stimulator antibody conjugate in patients with HER2+ malignancies[J]. Cancer immunology research， 2022， 10（12）：1441-1461.

基金资助

甘肃省自然科学基金(23JRRA1301)

兰大二院引进人才计划项目(yjrckyqdj-2024-02)

甘肃省自然科学基金(24JRRA1103)

甘肃省联合科研基金(24JRRA931)

陇南市科技计划项目(2024CX12)

陇南市社会化出资项目(2021-SZ-19)